From extracellular to intracellular targets, inhibiting MAP kinases in treatment of Crohn's disease

Annals of the New York Academy of Sciences

Volumn 973, Issue , 2002, Pages 349-358

  Van Den Blink, Bernt ^a   Ten Hove, Tessa ^a   Van Den Brink, Gijs R ^a   Peppelenbosch, Maikel P ^a   Van Deventer, Sander J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Crohn's disease; Cytokines; Human; Inflammation; Mitogen activated protein kinases; Th1 Th2 cells; Therapy

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

CELL DIFFERENTIATION; CONFERENCE PAPER; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; TH1 CELL;

EID: 0036961905     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04664.x     Document Type: Conference Paper

References (60)

1. NEURATH, M.F., et al. 1996. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 2: 998-1004.
2. SCHREIBER, S., S. NIKOLAUS & J. HAMPE. 1998. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42: 477-484.
3. ROGLER, G., et al. 1998. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115: 357-369.
4. ARDITE, E., et al. 1998. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br. J. Pharmacol. 124: 431-433.
5. THIELE, K., et al. 1999. Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut 45: 693-704.
6. HOMMES, D., et al. 2002. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122: 7-14.
7. KYRIAKIS, J.M. & J. AVRUCH. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81: 807-869.
8. HAN, J., et al. 1994. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265: 808-811.
9. LEE, J.C., et al. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746.
10. READ, M.A., et al. 1997. Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J. Biol. Chem. 272: 2753-2761.
11. NICK, J.A., et al. 1999. Selective activation and functional significance of p38alpha mitogen- activated protein kinase in lipopolysaccharide-stimulated neutrophils. J. Clin. Invest. 103: 851-858.
12. MACKAY, K. & D. MOCHLY-ROSEN. 1999. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. J. Biol. Chem. 274: 6272-6279.
13. CHEN, C.C. & J.K. WANG. 1999. p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. Mol. Pharmacol. 55: 481-488.
14. KIM, S.C., et al. 1999. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood 93: 3893-3899.
15. MILELLA, M., et al. 2001. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J. Clin. Invest. 108: 851-859.
16. GEE, J.M., et al. 2001. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer 95: 247-254.
17. EGERTON, M., D.R. FITZPATRICK & A. KELSO. 1998. Activation of the extracellular signal-regulated kinase pathway is differentially required for TCR-stimulated production of six cytokines in primary T lymphocytes. Int. Immunol. 10: 223-229.
18. VAN DER BRUGGEN, T., et al. 1999. Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway. Infect. Immun. 67: 3824-3829.
19. TOURNIER, C., et al. 2001. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev. 15: 1419-1426.
20. DAVIS, R.J. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
21. BENNETT, B.L., et al. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 98: 13681-1366.
22. DONG, C., et al. 1998. Defective T cell differentiation in the absence of Jnk1. Science 282: 2092-2095.
23. YANG, D.D., et al. 1998. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 9: 575-585.
24. VAN DEVENTER, S.J. 2000. Immunotherapy of Crohn's disease. Scand. J. Immunol. 51: 18-22.
25. TARGAN, S.R., et al. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337: 1029-1035.
26. VAN DULLEMEN, H.M., et al. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135.
27. HOFFMEYER, A., et al. 1999. Different mitogen-activated protein kinase signaling pathways cooperate to regulate tumor necrosis factor alpha gene expression in T lymphocytes. J. Biol. Chem. 274: 4319-4327.
28. ZHU, W., et al. 2000. Regulation of TNF expression by multiple mitogen-activated protein kinase pathways. J. Immunol. 164: 6349-6358.
29. CARTER, A.B., M.M. MONICK & G.W. HUNNINGHAKE. 1999. Both Erk and p38 kinases are necessary for cytokine gene transcription. Am. J. Resp. Cell. Mol. Biol. 20: 751-758.
30. MEANS, T.K.. et al. 2000. Activation of TNF-alpha transcription utilizes distinct MAP kinase pathways in different macrophage populations. J. Leuk. Biol. 67: 885-893.
31. VAN DEN BLINK, B., et al. 2001. p38 mitogen-activated protein kinase inhibition increases cytokine release by macrophages In vitro and during infection in vivo. J. Immunol. 166: 582-587.
32. BADGER, A.M., et al. 1996. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279: 1453-1461.
33. NICK, J.A., et al. 2000. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J. Immunol. 164: 2151-2159.
34. KOTLYAROV, A., et al. 1999. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol. 1: 94-97.
35. PARRONCHI, P., et al. 1997. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 150: 823-832.
36. PIZARRO, T.T., et al. 1999. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J. Immunol. 162: 6829-6835.
37. SIEGMUND, B., et al. 2001. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281: R1264-273.
38. ZHANG, S. & M.H. KAPLAN. 2000. The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-gamma expression. J. Immunol. 165: 1374-1380.
39. VISCONTI, R., et al. 2000. Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity. Blood 96: 1844-1852.
40. VERHAGEN, C.E., et al. 2000. Residual type 1 immunity in patients genetically deficient for interleukin 12 receptor beta 1 (IL-12Rbeta1): evidence for an IL-12Rbeta1-independent pathway of IL-12 responsiveness in human T cells. J. Exp. Med. 192: 517-528.
41. RE, F. & J.L. STROMINGER. 2001. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 26: 26.
42. LU, H.T., et al. 1999. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J. 18: 1845-1857.
43. HOVE, T.T., et al. 2002. Inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 50: 507-512.
44. MARRIOTT, J.B., I.A. CLARKE & A.G. DALGLEISH. 2001. Inhibition of p38 MAP kinase during cellular activation results in IFN-gamma-dependent augmentation of IL-12 production by human monocytes/macrophages. Clin. Exp. Immunol. 125: 64-70.
45. THOMASSEN, E., et al. 1998. Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. J. Interferon Cytokine Res. 18: 1077-1088.
46. KALINA, U., et al. 2000. IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21. J. Immunol. 165: 1307-1313.
47. CRAWLEY, J.B., et al. 1997. T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J. Biol. Chem. 272: 15023-15027.
48. HUNT, A.E., et al. 1999. Role of interleukin (IL)-2 receptor beta-chain subdomains and Shc in p38 mitogen-activated protein (MAP) kinase and p54 MAP kinase (stress-activated protein kinase/c-Jun N-terminal kinase) activation. IL-2-driven proliferation is independent of p38 and p54 MAP kinase activation. J. Biol. Chem. 274: 7591-7597.
49. RINCON, M. 2001. MAP-kinase signaling pathways in T cells. Curr. Opin. Immunol. 13: 339-345.
50. NISHINA, H., et al. 1997. Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes. J. Exp. Med. 186: 941-953.
51. 2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation. J. Exp. Med. 193: 317-328.
52. YAMASHITA, M., et al. 1999. T cell antigen receptor-mediated activation of the Ras/mitogenactivated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. Proc. Natl. Acad. Sci. USA 96: 1024-1029.
53. RINCON, M., et al. 1998. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 17: 2817-2829.
54. LU, B., et al. 2001. GADD45gamma mediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector TH1 cells. Immunity 14: 583-590.
55. YANG, J., et al. 2001. 1L-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. Nat. Immunol. 2: 157-164.
56. NAKANISHI, K. 2001. Innate and acquired activation pathways in T cells. Nat. Immunol. 2: 140-142.
57. WAETZIG, G.H., et al. 2001. Differential activity and expression of mitogen-activated protein kinases in inflammatory bowel disease. Proc. Digest. Dis. Wk. Abstract no 2657.
58. HAN, Z., et al. 1999. Jun N-terminal kinase in rheumatoid arthritis. J. Pharmacol. Exp. Ther. 291: 124-130.
59. ZU, Y.L., et al. 1998. p38 mitogen-activated protein kinase activation is required for human neutrophil function triggered by TNF-alpha or FMLP stimulation. J. Immunol. 160: 1982-1989.
60. DOWNEY, G.P., et al. 1998. Importance of MEK in neutrophil microbicidal responsiveness. J. Immunol. 160: 434-443.